Ziwen Liang1, Qinan Wu2, Bing Chen2, Peiwu Yu3, Hongliang Zhao3, Xinshou Ouyang4. 1. Department of Endocrinology, Southwest Hospital of Third Military Medical University, Chongqing 400038, China; Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: ziwen.liang9@gmail.com. 2. Department of Endocrinology, Southwest Hospital of Third Military Medical University, Chongqing 400038, China. 3. Department of General Surgery, Southwest Hospital of Third Military Medical University, Chongqing 400038, China. 4. Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Abstract
AIMS: The aim of this study was to evaluate the effect of laparoscopic Roux-en-Y gastric bypass (RYGB) surgery compared with usual care with and without Exenatide therapy in obese people with type 2 diabetes mellitus (T2DM) and hypertension. METHODS: 108 obese T2DM with hypertension were enrolled and randomly allocated to usual care (group A), usual care plus Exenatide (group B), and RYGB surgery (group C). Demographic characteristics, metabolic parameters and cardiac structure/function along with inflammatory cytokines were measured and compared before and after 12 months. RESULTS: At 12 months, diabetes remission had occurred in no patients in groups A and B versus 90% in group C, and there was a significant decrease in requirement of antihypertensive drugs in group C compared with groups A and B (P<0.05). Other parameters (body mass index, hemoglobin A1c, homeostasis model assessment of insulin resistance, lipids), inflammation index (high sensitivity C-reactive protein, tumor necrosis factor-α, high molecular weight adiponectin) and cardiac structure (left ventricular mass index) were significantly improved in groups B and C, but patients in group C had the greatest degree of improvement (P<0.05). CONCLUSION:RYGB surgery improves a number of parameters including cardiovascular function in obese hypertensive people with T2DM. This is likely to be due to, at least in part, an improvement in the abnormal metabolic panel and to reduced inflammation.
RCT Entities:
AIMS: The aim of this study was to evaluate the effect of laparoscopic Roux-en-Y gastric bypass (RYGB) surgery compared with usual care with and without Exenatide therapy in obesepeople with type 2 diabetes mellitus (T2DM) and hypertension. METHODS: 108 obese T2DM with hypertension were enrolled and randomly allocated to usual care (group A), usual care plus Exenatide (group B), and RYGB surgery (group C). Demographic characteristics, metabolic parameters and cardiac structure/function along with inflammatory cytokines were measured and compared before and after 12 months. RESULTS: At 12 months, diabetes remission had occurred in no patients in groups A and B versus 90% in group C, and there was a significant decrease in requirement of antihypertensive drugs in group C compared with groups A and B (P<0.05). Other parameters (body mass index, hemoglobin A1c, homeostasis model assessment of insulin resistance, lipids), inflammation index (high sensitivity C-reactive protein, tumor necrosis factor-α, high molecular weight adiponectin) and cardiac structure (left ventricular mass index) were significantly improved in groups B and C, but patients in group C had the greatest degree of improvement (P<0.05). CONCLUSION: RYGB surgery improves a number of parameters including cardiovascular function in obese hypertensivepeople with T2DM. This is likely to be due to, at least in part, an improvement in the abnormal metabolic panel and to reduced inflammation.
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Ali Aminian; Stacy A Brethauer; Sankar D Navaneethan; Rishi P Singh; Claire E Pothier; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Zhamak Khorgami; Saeed Shoar; Alan A Saber; C Anthony Howard; Goodarz Danaei; Guido M Sclabas Journal: Obes Surg Date: 2019-03 Impact factor: 4.129
Authors: Sayeed Ikramuddin; Charles J Billington; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael G Sarr; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Joyce L Schone; Amy E Olofson; Heather A Bainbridge; Patricia S Laqua; Qi Wang; Judith Korner Journal: Lancet Diabetes Endocrinol Date: 2015-05-12 Impact factor: 32.069
Authors: Stefany D Primeaux; Taniya de Silva; Tony H Tzeng; Monica C Chiang; Daniel S Hsia Journal: Rev Endocr Metab Disord Date: 2016-06 Impact factor: 6.514
Authors: Adam C Celio; Kevin R Kasten; Matthew B Burruss; Walter J Pories; Konstantinos Spaniolas Journal: Surg Endosc Date: 2016-07-21 Impact factor: 4.584